Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S. Bouazza N, et al. Among authors: hien h. Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1. Antimicrob Agents Chemother. 2010. PMID: 20516271 Free PMC article. Clinical Trial.
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Tréluyer JM. Hirt D, et al. Among authors: hien h. Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13. doi: 10.1128/AAC.01594-08. Epub 2009 Jul 27. Antimicrob Agents Chemother. 2009. PMID: 19635964 Free PMC article. Clinical Trial.
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group. Gabillard D, et al. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821. J Acquir Immune Defic Syndr. 2013. PMID: 23274931 Free PMC article.
Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.
De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group. De Beaudrap P, et al. Among authors: hien h. Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222. Pediatr Infect Dis J. 2013. PMID: 23099424
Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial.
Kesho Bora Study Group. Kesho Bora Study Group. Clin Infect Dis. 2012 Aug;55(3):449-60. doi: 10.1093/cid/cis461. Epub 2012 May 9. Clin Infect Dis. 2012. PMID: 22573845 Free PMC article. Clinical Trial.
145 results